In early October, the U.S. Food and Drug Administration approved Paratek Pharmaceuticals’ new antibiotic Nuzyra, which kills bacteria associated with skin and lung infections.
The approval was notable because there are so few new antibiotics coming onto the market, , says journalist Maryn McKenna in Wired magazine, largely because most drug companies don’t think antibiotics — which have wiped out the threat of many infectious diseases — to be worth the investment.
The problem is a unique business and policy dilemma for society. Continue reading
PHOENIX – To picture a future in which antibiotics no longer work, all we have to do is look at the past – at the United States before the 1940s when simple infections accounted for a third of all deaths.
“When an antibiotic resistance develops anywhere, it’s a threat to people everywhere,” said Elizabeth Jungman, director of The Pew Charitable Trusts’ public health programs, speaking at a panel on Friday at Health Journalism 2018 that painted a chilling but prescient view of what could happen if and when antibiotics stop working, and we don’t have enough new drugs in the pipeline. “We know what a post-antibiotic world could look like because we lived in a pre-antibiotic world.” Continue reading
The latest news about the arrival in the U.S. of a deeply concerning “superbug” justifiably injected alarm into the headlines recently.
It was not actually a new bacteria that arrived but the “dreaded gene mcr-1,” a mutation which “confers protection against colistin, the last remaining antibiotic that works against a broad family of bacteria that have already acquired resistance to all the other antibiotics used against them,” as AHCJ board member Maryn McKenna described in her piece at her Germination blog at National Geographic. Continue reading